FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies
If that proposal is finalized, the exclusion would likely limit the mass compounding of those medicines unless they appear on the FDA's drug shortage list.
FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies basliginda one cikan gelisme: If that proposal is finalized, the exclusion would likely limit the mass compounding of those medicines unless they appear on the FDA's drug shortage list.
Fonvera editor notu: Haberin piyasa etkisini izlemek icin ilgili varlik sayfalari ve ekonomik takvim akisi birlikte okunmalidir.